martelletti paolo (114 risultati)

217 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Sprache: Englisch.

Condizione: New. In.

Paperback. Condizione: new. Paperback. Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development. Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condizione: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | This book provides up-to-date information on all aspects of the comorbidities that are associated with the headache disorders commonly seen in the primary care and hospital settings, including migraine, tension-type headache, and cluster headache. The coverage is wide ranging and encompasses all of the well-established comorbidities: cardio- and cerebrovascular disease, psychiatric conditions, epilepsy, sleep disorders, and various pain disorders, such as visceral pain, fibromyalgia, orofacial pain, and neuropathic pain. Individual chapters are also devoted to obesity and other metabolic comorbidities and to the comorbidities associated specifically with pediatric headaches. The information provided will assist readers in understanding the complex relationships between headache disorders and these various conditions and in delivering effective care that reflects the latest knowledge. The book is designed to meet the daily practice needs of general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students. It is published as part of the series Headache, which is endorsed by the European Headache Federation ¿ EHF.

Condizione: New.

Hardcover. Condizione: new. Hardcover. Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Paperback. Condizione: new. Paperback. Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development. Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

Condizione: As New. Unread book in perfect condition.

Condizione: As New. Unread book in perfect condition.

Condizione: New.

Hardcover. Condizione: new. Hardcover. Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development. Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.

Taschenbuch. Condizione: Neu. Neuware -Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 184 pp. Englisch.

Condizione: New.

Gebunden. Condizione: New.

Condizione: New. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 7-12 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.

Paperback. Condizione: New. NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Taschenbuch. Condizione: Neu. Neuware -Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 120 pp. Englisch.

Condizione: New.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Hardcover. Condizione: new. Hardcover. The proposed book stands as a pioneering and unique contribution in the literary landscape, addressing a critical intersection of health and sustainable development. Migraine, often relegated to the sidelines in discussions about global health, emerges as a neglected disorder with profound implications for the achievement of SDG3 ensuring healthy lives and promoting well-being for all at all ages.What sets this book apart is its strong commitment to unraveling the complexities surrounding migraine within the context of SDG3. Migraine, despite its prevalence and debilitating impact on individuals, has long been overshadowed by other health concerns. This book challenges this neglect, providing an in-depth exploration of the socio-economic factors contributing to the oversight of migraine and proposing actionable strategies aligned with SDG3 to rectify this global health blind spot.The scope of the book extends far beyond conventional medical discourse, delving into the economic, social, and cultural dimensions of migraine's impact. It not only elucidates the physiological aspects of the disorder but also addresses the intricate web of factors hindering its recognition and adequate treatment on a global scale. By intertwining the narrative with SDG3, the book aims to ignite a paradigm shift, compelling stakeholders to recognize migraine as a pivotal player in the pursuit of universal health.This book's target readership comprises not only neurologists seeking a comprehensive understanding of migraine but also brain health advocates worldwide. By appealing to a diverse audience, it aspires to foster a collaborative approach to tackle migraine within the framework of SDG3. The book's unique blend of medical insights, global health perspectives, and advocacy strategies makes it an indispensable resource for those committed to advancing neurological health and realizing the vision of SDG3 on a global scale. In essence, this book is poised to be a catalyst for change, altering the trajectory of how migraine is perceived, treated, and integrated into the broader discourse of sustainable development. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Condizione: New.

Hardcover. Condizione: Brand New. 182 pages. 9.25x6.10x0.59 inches. In Stock.

Condizione: As New. Unread book in perfect condition.

Condizione: New. In.

Hardcover. Condizione: Like New. Like New. book.